(NASDAQ: FDMT) 4d Molecular Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.25%.
4d Molecular Therapeutics's earnings in 2025 is -$196,144,000.On average, 7 Wall Street analysts forecast FDMT's earnings for 2025 to be -$170,996,413, with the lowest FDMT earnings forecast at -$185,408,794, and the highest FDMT earnings forecast at -$142,909,549. On average, 6 Wall Street analysts forecast FDMT's earnings for 2026 to be -$176,381,207, with the lowest FDMT earnings forecast at -$213,430,274, and the highest FDMT earnings forecast at -$134,036,080.
In 2027, FDMT is forecast to generate -$174,550,470 in earnings, with the lowest earnings forecast at -$225,105,891 and the highest earnings forecast at -$134,036,080.